La tunisie Medicale - 2021 ; Vol 99 ( n°02 ) : 189-200
[ 365 times seen ]
Summary

Background: Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease and liver cancer related deaths in Tunisia.
Aim: Perform a systematic review on viral hepatitis C in Tunisia between 1991 and 2019.
Methods: A global search of HCV-specific documentation in Tunisia (1991-2019) in bibliographic data search sites.
Results: Tunisia is a low endemic country for hepatitis C with a prevalence that not exceed 1% in the general population. Several studies have focused on populations at risk of HCV contamination such as hemodialysis and polytransfused patients. The prevalence of hepatitis C is higher in these groups. In relatively small series, a clear predominance of genotype 1 and subtype 1b has been reported in Tunisia with a lower co-circulation of the other genotypes.
Several polymorphisms of cytokine and chemokine genes can influence the clearance or persistence of HCV infection. Tunisian studies have focused on the efficacy of conventional dual therapy (pegylated IFN + ribavirin) by analyzing the predictive factors linked to SVR and mutations associated with resistance to viral inhibitors. No publication has discussed the effectiveness of new direct-acting antivirals in Tunisia.
Conclusion: This review of the literature provides an update on the status of hepatitis C in Tunisia and reveals a lack of investigations on new direct-acting antivirals.

Key - Words
Article
Login
E-mail :
Password :
Remember Me Forgot password? Sign UP
Archives
2021
January
February
March
April
May
June
July
August
September
October
November
December
Keywords most used
treatment Child diagnosis surgery prognosis Tunisia Children Crohn’s disease Breast cancer Cancer screening epidemiology Ulcerative colitis mammography tuberculosis
Newsletter
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !